Metabolic Solutions Development Company

Metabolic Solutions Development Company is developing innovative therapeutics to treat diabetes and related symptoms of metabolic syndrome. These therapeutic agents are PPARy-sparing insulin sensitizers that have improved profiles over the first generation thiazolidinedione class of insulin sensitizers. In addition to having reduced side effects, PPARy-sparing insulin sensitizers should improve cardiovascular outcomes by not only lowering glucose but also significantly improving lipid profiles and blood pressure. These agents may also have the potential to prevent progression of type 2 diabetes and to affect the progression of cardiovascular disease in non-diabetic patients.